Aug 14, 2023 8:30am EDT FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
Aug 2, 2023 8:30am EDT MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
